Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG

J. C. Britell, D. L. Ahmann, H. F. Bisel, S. Frytak, J. N. Ingle, J. Rubin, J. R. O'Fallon

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The value of immunotherapy as an adjuvant to chemotherapy for advanced breast cancer is an unsettled question. To clarify this issue, 71 women with measurable or evaluable metastatic breast cancer were randomized to receive cyclophosphamide, 5-fluorouracil, and prednisone (CFP) with or without methanol-extracted residue of Bacillus Calmette-Guerin (MER). The total regression rates were 52% (CFP) and 39% (CFP+MER), including complete regression rates of 13% (CFP) and 6% (CFP+MER). The median duration of regressions for CFP-treated patients was 257-261 days and for CFP + MER-treated patients was 385 days. The median time to progression was 248-261 days in the CFP group and 159 days in the CFP-MER group. Projected median survival for both treatment groups in 20 months. Immunotherapy (MER) as used in this study does not appear to augment regression rates or survival for patients with advanced breast cancer receiving CFP.

Original languageEnglish (US)
Pages (from-to)345-350
Number of pages6
JournalCancer Clinical Trials
Volume2
Issue number4
StatePublished - Dec 1 1979

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG'. Together they form a unique fingerprint.

  • Cite this

    Britell, J. C., Ahmann, D. L., Bisel, H. F., Frytak, S., Ingle, J. N., Rubin, J., & O'Fallon, J. R. (1979). Treatment of advanced breast cancer with cyclophosphamide, 5-fluorouracil, and prednisone with and without methanol-extracted residue of BCG. Cancer Clinical Trials, 2(4), 345-350.